Welcome to our dedicated page for Dare Bioscience SEC filings (Ticker: DARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daré Bioscience, Inc. filings document a women’s health biotechnology issuer with product and pipeline disclosures, operating-result updates, and capital-structure activity. Recent 8-K reports cover financial results, Regulation FD presentations, and unregistered sales tied to a Regulation A unit offering composed of Series A Convertible Preferred Stock and warrants to purchase common stock.
Proxy and governance filings describe annual meeting matters, director elections, executive compensation, equity awards, board classification, and stockholder voting procedures. The record also includes disclosure around offering statements, preferred-stock conversion terms, warrant exercise terms, and financing activity associated with advancing women’s health products and clinical programs.
Daré Bioscience, Inc. (DARE) reports that on September 10, 2026, its board of directors approved an amendment to the company’s Third Amended and Restated By-Laws to change the stockholder meeting quorum standard. The quorum requirement was reduced from holders of a majority in voting power of outstanding shares entitled to vote to holders of at least one-third of the voting power of such shares, effective immediately. The amendment text is provided as an exhibit and incorporated by reference.
Daré Bioscience, Inc. (DARE) furnished a corporate presentation as an exhibit to a current report under a Regulation FD disclosure. The presentation is dated September 9, 2026 and may be used in meetings with securities market participants and others starting on that date.
The presentation will also be made available in the Investors section of Daré’s website under “Presentations, Events & Webcasts.” The furnished materials, including Exhibit 99.1, are not deemed filed for purposes of Section 18 of the Exchange Act or incorporated by reference into other securities filings, except if specifically referenced.
Daré Bioscience, Inc. (DARE) has filed a resale prospectus covering up to 8,934,345 shares of common stock for selling stockholders. This includes 8,759,162 shares issuable upon exercise of Series A and Series B common warrants and 175,183 shares issuable upon exercise of placement agent warrants. Daré is not selling shares and will not receive proceeds from stockholder resales, but may receive up to approximately $12.4 million if all warrants are exercised for cash at exercise prices of $1.37 and $2.1235 per share.
The warrants were issued in an August 2026 financing that combined a registered direct offering with a concurrent private placement and are exercisable only after required Nasdaq stockholder approval, with built-in beneficial ownership limits of 4.99% or 9.99%. Shares outstanding were 19,669,083 as of August 20, 2026; this is a baseline figure, not the amount being offered. Daré highlights a women’s health–focused pipeline, a new Section 503B compounding and consumer health strategy, substantial ongoing capital needs, a prior going-concern emphasis in its 2025 audit report, and continued risk around maintaining its Nasdaq Capital Market listing pending a panel decision.
Dare Bioscience, Inc. (DARE) reports that Lind Global Fund III LP, Lind Global Partners III LLC, and Jeff Easton have jointly filed as significant shareholders on a Schedule 13G. Each reporting person is deemed to beneficially own 1,094,890 shares of common stock, representing 5.65% of the outstanding common stock, with sole voting and dispositive power over these shares.
The ownership position is structured as (i) 1,094,890 common shares, (ii) 1,094,890 Series A Warrants, and (iii) 1,094,890 Series B Warrants. A 4.99% beneficial ownership limitation in the warrants caps how many shares can be owned through conversion at any time, so aggregate beneficial ownership is limited to 1,094,890 shares.
Daré Bioscience, Inc. (DARE) has filed a Form S-1 to register for resale up to 8,934,345 shares of common stock issued or issuable to investors and the placement agent from an August 2026 financing. All shares are being offered by selling stockholders; Daré is not selling shares in this registration.
The registered shares consist of 8,759,162 shares underlying Series A and Series B common warrants (including pre-funded warrants) and 175,183 shares underlying placement agent warrants. Daré will not receive proceeds from stockholder resales, but could receive up to about $12.4 million if all warrants are exercised for cash, which it plans to use for working capital, 503B compounding and consumer health initiatives, and R&D.
Daré describes a women’s health portfolio spanning contraception, menopause, sexual and vaginal health, and infectious disease, plus a dual-path model using both FDA approval and Section 503B compounding. It highlights new 503B and consumer products, significant ongoing capital needs, a recent Nasdaq Listing Rule 5550(b) deficiency under review by a Nasdaq hearing panel, and an auditor’s going-concern paragraph in its 2025 financial statements.
Dare Bioscience, Inc. (DARE) reports that L1 Capital Global Opportunities Master Fund, Ltd. has filed a Schedule 13G as a beneficial owner of its common stock. L1 Capital reports beneficial ownership of 2,028,885 Dare common shares (including warrant-linked shares), representing 9.99% of the common stock class.
The position consists of 1,094,890 shares of common stock and 933,995 Series A Warrants, all subject to a 9.99% beneficial ownership limitation. Additional 160,895 Series A Warrants and 1,094,890 Series B Warrants are not counted due to this limitation. The reported ownership percentage is based on 19,375,189 shares of Dare common stock outstanding, which gives no effect to any exercise of Pre-Funded Warrants. L1 Capital has sole voting and dispositive power over the 2,028,885 shares.
Dare Bioscience, Inc. (DARE) filed a Form D for a new exempt securities offering under Regulation D, Rule 506(b). The total offering amount is $12,375,054, which reflects potential cash proceeds if all warrants are exercised.
The offering covers warrants and the common stock issuable upon exercise, consisting of 8,759,162 shares at an exercise price of $1.37 per share and 175,183 shares at $2.1235 per share. As of this notice, no warrants have been exercised. Ladenburg Thalmann & Co. Inc. is listed for sales compensation, and reported finders’ fees are $0.
Daré Bioscience entered into a securities purchase agreement with institutional investors for a registered direct offering of up to 4,379,581 shares of common stock (or pre-funded warrants in lieu thereof) at $1.37 per share ($1.3699 per pre-funded warrant), plus a concurrent private placement of Series A and Series B common stock warrants covering up to 4,379,581 shares each. Pre-funded warrants are immediately exercisable at $0.0001 per share, while the Series A and B warrants have a $1.37 exercise price and become exercisable only after required stockholder approval under Nasdaq rules, with five-year and two-year terms, respectively, from the initial exercise date. Gross proceeds are expected to be approximately $6.0 million before fees, to be used for working capital and general corporate purposes, including 503B compounding and consumer health strategies, R&D, and G&A costs. Ladenburg Thalmann is acting as exclusive placement agent, receiving a 7.0% cash fee, up to $105,000 of expense reimbursement, and warrants equal to 4.0% of the Shares and pre-funded warrants sold, with a $2.12 exercise price and a five-year term.
Daré Bioscience, Inc. is conducting a primary shelf takedown offering of 4,085,687 shares of common stock and 293,894 pre-funded warrants at $1.37 per share and $1.3699 per pre-funded warrant, for gross proceeds of $5,999,996.58 and estimated net proceeds of about $5.4 million.
Each pre-funded warrant is immediately exercisable for one share at $0.0001 and is subject to a 4.99% (or 9.99%) beneficial ownership limitation. In a concurrent private placement, Daré is issuing Series A and B warrants to purchase up to 8,759,162 additional shares and/or pre-funded warrants, exercisable only if stockholders approve under Nasdaq rules.
Common shares outstanding will increase to about 19.4 million (or 19.7 million if all pre-funded warrants are exercised). The company plans to use net proceeds for working capital and general corporate purposes, including its 503B compounding and consumer health strategies and R&D, amid disclosed going-concern and Nasdaq listing risks.